Powered by

Innovent's phase III clinical trial of anti-PD-1 antibody Tyvyt reports first patient dosing

Jan 02, 2019 - Global Banking News

Innovent Biologics Inc (Innovent) (HKEX: 01801), a biopharmaceutical company that develops and commercialises high quality medicines, announced on Tuesday the dosing of the first patient in a phase III clinical trial (ORIENT-15) that is to evaluate Tyvyt (fully human anti-PD-1 therapeutic monoclonal antibody) (generic name: sintilimab injection), in combination with paclitaxel and cisplatin, as first-line treatment in patients with advanced, recurrent or metastatic oesophageal squamous cell carc...